521 related articles for article (PubMed ID: 8687261)
1. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
Singh G; Ramey DR; Morfeld D; Shi H; Hatoum HT; Fries JF
Arch Intern Med; 1996 Jul; 156(14):1530-6. PubMed ID: 8687261
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of NSAID induced gastrointestinal complications.
Singh G; Triadafilopoulos G
J Rheumatol Suppl; 1999 Apr; 56():18-24. PubMed ID: 10225536
[TBL] [Abstract][Full Text] [Related]
3. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System.
Singh G; Rosen Ramey D
J Rheumatol Suppl; 1998 May; 51():8-16. PubMed ID: 9596549
[TBL] [Abstract][Full Text] [Related]
4. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
Wolfe F; Hawley DJ
J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
[TBL] [Abstract][Full Text] [Related]
5. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
Rahme E; Pettitt D; LeLorier J
Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
7. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
Fries JF; Bruce B
J Rheumatol; 2003 Oct; 30(10):2226-33. PubMed ID: 14528521
[TBL] [Abstract][Full Text] [Related]
8. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
[TBL] [Abstract][Full Text] [Related]
9. Identification of patients at risk for gastropathy associated with NSAID use.
Fries JF; Miller SR; Spitz PW; Williams CA; Hubert HB; Bloch DA
J Rheumatol Suppl; 1990 Feb; 20():12-9. PubMed ID: 2325051
[TBL] [Abstract][Full Text] [Related]
10. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
11. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.
Harris CL; Raisch DW; Abhyankar U; Marfatia S; Campbell HM; Sather MR
Ann Pharmacother; 2006 Nov; 40(11):1924-31. PubMed ID: 17047140
[TBL] [Abstract][Full Text] [Related]
12. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis.
Steen KS; Nurmohamed MT; Visman I; Heijerman M; Boers M; Dijkmans BA; Lems WF
Ann Rheum Dis; 2008 Feb; 67(2):256-9. PubMed ID: 17604285
[TBL] [Abstract][Full Text] [Related]
13. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
[TBL] [Abstract][Full Text] [Related]
14. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
[TBL] [Abstract][Full Text] [Related]
15. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
16. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs.
Agrawal NM; Aziz K
J Rheumatol Suppl; 1998 May; 51():17-20. PubMed ID: 9596550
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
[TBL] [Abstract][Full Text] [Related]
18. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis.
Fries JF; Murtagh KN; Bennett M; Zatarain E; Lingala B; Bruce B
Arthritis Rheum; 2004 Aug; 50(8):2433-40. PubMed ID: 15334455
[TBL] [Abstract][Full Text] [Related]
19. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms.
Thomas J; Straus WL; Bloom BS
Am J Gastroenterol; 2002 Sep; 97(9):2215-9. PubMed ID: 12358235
[TBL] [Abstract][Full Text] [Related]
20. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
Schiff M; Peura D
Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):25-35. PubMed ID: 22149579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
